bioRxiv · 10.1101/2021.02.01.429110
Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology.
Abstract
Co-circulation of SARS-CoV-2 and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in co-infected patients. The lack of a readily available COVID-19 vaccine has reinforced the importance of influenza vaccine programmes during the COVID-19 pandemic. Live Attenuated Influenza Vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration might influence the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV (QLAIV) was administered to ferrets 3 days pre- or post-SARS-CoV-2 infection. LAIV administration did not exacerbate SARS-CoV-2 disease course or lung pathology with either regimen. Additionally, LAIV administered prior to SARS-CoV-2 infection significantly reduced SARS-CoV-2 replication and shedding in the upper respiratory tract (URT). We conclude that LAIV administration in close proximity to SARS-CoV-2 infection does not exacerbate mild disease and can reduce SARS-CoV-2 shedding.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Ryan, K. A., Schewe, K. E., Crowe, J., Fotheringham, S. A., Hall, Y., Humphreys, R., Marriott, A. C., Paterson, J., Rayner, E., Salguero, F. J., Watson, R. J., Whittaker, C. J., Carroll, M. W., Dibben, O.. 2021-02-01. Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology.. https://doi.org/10.1101/2021.02.01.429110
Cite the original work for its findings. Save a collection to share your selection of sources.